Patents by Inventor Nicholas Glanville

Nicholas Glanville has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CANCER THERAPY WITH LIVE ATTENUATED BACTERIA
    Publication number: 20240226190
    Abstract: The present invention relates to the field of cancer therapy. In particular, the present invention relates to a first composition comprising a live attenuated bacterium for use in the treatment, prevention, reduction, inhibition, prevention of recurrence, or control of a neoplastic disease in a subject being or intended to be administered a second composition comprising a live attenuated bacterium, said bacterium being the same or different to that of the first composition and methods thereof.
    Type: Application
    Filed: July 28, 2022
    Publication date: July 11, 2024
    Inventors: Livija Deban, Nicholas Glanville
  • Induction of cross-reactive cellular response against rhinovirus antigens
    Patent number: 9937252
    Abstract: The present invention concerns: a) an isolated peptide comprising an amino acid sequence which is at least 90% identical to the VP4 amino acid sequence of a rhinovirus, or an isolated polynucleotide comprising a nucleic acid sequence encoding said peptide, placed under the control of the elements necessary for its expression in a mammalian cell; and/or b) an isolated peptide comprising an amino acid sequence of at least 100 amino acids which is at least 90% identical to an amino acid sequence located in the last 363 C-terminal amino acids of the RNA polymerase of a rhinovirus, or an isolated polynucleotide comprising a nucleic acid sequence encoding said peptide, placed under the control of the elements necessary for its expression in a mammalian cell; and c) a Th1 adjuvant when said immunogenic composition comprises one or more of said isolated peptides.
    Type: Grant
    Filed: February 6, 2014
    Date of Patent: April 10, 2018
    Inventors: Gary McLean, Walton Ross, Sebastian Johnston, Nathan Wylie Bartlett, Bruno Guy, Yves Girerd-Chambaz, Valerie Lecouturier, Jeffrey Almond, Nicholas Glanville, Nicolas Burdin
  • INDUCTION OF CROSS-REACTIVE CELLULAR RESPONSE AGAINST RHINOVIRUS ANTIGENS
    Publication number: 20160095916
    Abstract: The present invention concerns: a) an isolated peptide comprising an amino acid sequence which is at least 90% identical to the VP4 amino acid sequence of a rhinovirus, or an isolated polynucleotide comprising a nucleic acid sequence encoding said peptide, placed under the control of the elements necessary for its expression in a mammalian cell; and/or b) an isolated peptide comprising an amino acid sequence of at least 100 amino acids which is at least 90% identical to an amino acid sequence located in the last 363 C-terminal amino acids of the RNA polymerase of a rhinovirus, or an isolated polynucleotide comprising a nucleic acid sequence encoding said peptide, placed under the control of the elements necessary for its expression in a mammalian cell; and c) a Th1 adjuvant when said immunogenic composition comprises one or more of said isolated peptides.
    Type: Application
    Filed: February 6, 2014
    Publication date: April 7, 2016
    Applicants: SANOFI PASTEUR, IMPERIAL INNOVATIONS LIMITED
    Inventors: Gary McLean, Walton Ross, Sebastian Johnson, Nathan Bartlett, Bruno Guy, Yves Girerd-Chambaz, Valerie Lecouturier, Jeffrey Almond, Nicholas Glanville, Nicolas Burdin